Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 13/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28656278 | 0.88 | P2RY2 (0.53) | P2RY2P2RY6P2RY4ST6GAL1 | |
| SCHEMBL18785151 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL12595472 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL308618 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL532547 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL29360821 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL154172 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18785149 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL39904 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL18785150 | 0.87 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423877-A | Mutant tRNAs for codon expansion | 中外制药株式会社 | 2021-09-21 | — | — | CN | disclosed |